Navigation Links
Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
Date:10/26/2007

MONTREAL, Oct. 26 /PRNewswire/ - The IND proposes a randomized Phase III pivotal clinical trial that will compare SP1049C plus Best Supportive Care (BSC) versus BSC alone for the treatment of patients with advanced adenocarcinoma of the esophagus, gastroesophageal junction and stomach who have failed adjuvant or 1st or 2nd line chemotherapy. Supratek Pharma is Sponsor of the IND and will direct the clinical development program. The Company will initiate the clinical trial after completion of a Special Protocol Assessment (SPA) which is currently ongoing.

Oleg Romar, President and Chief Executive Officer, said, "The IND clearance by the FDA is a significant and exciting milestone in the clinical development program of our lead product. SP1049C is first among our unique family of nanomedicines. We believe that our Biotransport(TM) polymers' ability to provide novel mechanisms of action to drugs that have gone through clinical development, greatly speeds the overall development time, reduces risk and builds on approved platforms".

"The IND brings Supratek Pharma one step closer to creating an effective treatment for patients with metastatic disease who have failed available therapies and for whom no approved salvage therapies exist. We are dedicated to the clinical development of our product pipeline and to our commitment to provide novel therapeutics against drug resistant and metastatic cancers", said Dr. Christopher E. Newman, Vice-President and Chief Medical Officer of Supratek Pharma.

About SP1049C

-------------

Supratek's lead anticancer drug candidate, SP1049C, is based on Biotransport(TM) polymer technology. This drug is a proprietary composition of poloxamers with one of the most potent cytotoxic drugs, doxorubicin. Doxorubicin is among the most widely utilized anticancer drugs but is limited in its clinical use by inherent or induced drug resistance. While SP1049C retains the fundamental therapeutic characteristics of doxo
'/>"/>

SOURCE Supratek Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Jharkhand Pharmacies Refuse To Sell Viagra
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharma majors gear to supply anti-anthrax drug
11. Pharmacies in for a dose of bitter medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , ... August 28, 2015 , ... ... patient loyalty at a low cost. Personalized with practice contact information and logos, ... patients. Dental offices can also incorporate Calendars into seasonal mailings, thank you and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... announce its collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil ... features revolutionary Thermal Flavor Extraction™ technology, which delivers a variety of sizes and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Medicare-Medicaid Dual Eligibles Database have added comprehensive information on two new duals ... for a December 2015 launch; and Idaho’s partnership to revamp Blue Cross ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Plaintiffs ... as MDL 2545, Testosterone Replacement Therapy Products Liability Litigation, are in the midst ... custodial files the PSC may receive for corporate employees involved in the production ...
(Date:8/28/2015)... ... ... launched their new website this summer. The new user-friendly site has a ... design. Website users will now have an improved browsing experience on their phones, tablets, ... the monthly turf-tips email, and find a local Super-Sod store all from the convenience ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
... Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... a U.S. pharmaceutical company with its principal ... granted leave by the American,Arbitration Association ("AAA") ... defamation and breach of contract in a ...
... to be anti-inflammatory in several animal injury models. Recent ... and liver against lethal doses of endotoxin in rat ... transplantation. The influence of dietary glycine on oxidant-induced or ... article to be published on October 21, 2008 in ...
... International Osteoporosis Foundation (IOF) has backed the National Osteoporosis ... on the prevention and treatment of osteoporosis. ... National Societies said "we support any initiative that is ... in this instance we do not believe this is ...
... latest advances in,autism research, treatment and therapy will ... Lauderdale. The comprehensive four-day,conference, hosted by the National ... for November 13 through 16 at the Hyatt ... The conference will feature keynote speaker U.S. ...
... Wolters Kluwer, a,market leading global information services and ... of Robert Becker to the,position of President and ... Becker is currently CEO of Wolters Kluwer Law ... CEO of Wolters Kluwer Law &,Business (U.S.)., ...
... 31 SCOLR Pharma, Inc.,(Amex: DDD ) today ... Friday, November 7, 2008, at 8:30 a.m. Eastern. Daniel ... the conference call at 11:30,a.m. Eastern, to discuss the ... interested parties may participate in the,conference call by dialing ...
Cached Medicine News:Health News:Genesis Pharmaceuticals Files Counter Claims 2Health News:National Autism Conference to be Held in Weston, FL November 13-16 2Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 2Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 3Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 4Health News:SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern 2
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... Md., Jan. 31, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... a universal shelf registration statement on Form S-3 with ... effective by the SEC, the shelf registration statement will ...
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... announced that it will report its unaudited financial results ... before the U.S. market opens on February 18, 2011. ... 2011. The Company,s senior management will ...
Cached Medicine Technology:Vanda Pharmaceuticals Files Shelf Registration Statement 2Vanda Pharmaceuticals Files Shelf Registration Statement 3Vanda Pharmaceuticals Files Shelf Registration Statement 4China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011 2
The ultra micro tip for the new Eppendorf 2000/2100 series ultra micro pipettors provides accurate drawing and dispensing everytime....
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
... as both regular and filter tips. Sterilized ... more efficient sterilization and are delivered with ... of irradiation. Sterilized Diamond Tips are ready ... Diamond Tips are wrapped in medical device ...
This long 10 L tip features a MicroPoint design for the original Finnpipette 0.5-10 L and the new Finnpipette 0.5-10 L universal fit pipettors....
Medicine Products: